Sangamo Therapeutics, Inc.
- SGMOQ ยท OTC
- Biological Products, (No Diagnostic Substances)
- Richmond, CA
- 142 employees
- CIK 0001001233
Updated from SEC filings through
Top things to know
Executives
- Sandy Macrae PRESIDENT, CEO AND DIRECTOR 4, 2026-05-27
- Nathalie Dubois-Stringfellow SVP-CHIEF DEVELOPMENT OFFICER 4, 2026-05-27
- Scott B. Willoughby SVP, CHIEF LEGAL OFFICER, SECY 4, 2026-05-27
- Nikunj Jain Principal Accounting Officer 4, 2026-05-27
- Gregory D. Davis Head of Research & Technology 4, 2026-05-27
- Prathyusha Duraibabu PRINCIPAL FINANCIAL OFFICER 4, 2026-01-26
What leadership is saying
“During the first quarter, we advanced our rolling BLA submission for ST-920 and continued to progress our differentiated neurology pipeline”
Earnings press release (8-K Ex. 99.1), filed May 14, 2026
Sangamo Therapeutics, Inc is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in Richmond, CA. It trades as SGMOQ on OTC. Revenue was $39.6M in the fiscal year ending December 31, 2025, -31.6% from the year before. It reported about 142 employees. Sandy Macrae is PRESIDENT, CEO AND DIRECTOR.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $39.6M 10-K, 2026-03-30 | $57.8M 10-K, 2026-03-30 | $176M 10-K, 2025-03-17 | $111M 10-K, 2024-03-13 | $111M 10-K, 2024-03-13 |
| Operating income | -$121M 10-K, 2026-03-30 | -$104M 10-K, 2026-03-30 | -$274M 10-K, 2025-03-17 | -$201M 10-K, 2024-03-13 | -$183M 10-K, 2024-03-13 |
| SG&A | $34.9M 10-K, 2026-03-30 | $44.7M 10-K, 2026-03-30 | $61.2M 10-K, 2025-03-17 | $62.7M 10-K, 2024-03-13 | $63.2M 10-K, 2024-03-13 |
| Net income | -$123M 10-K, 2026-03-30 | -$97.9M 10-K, 2026-03-30 | -$258M 10-K, 2025-03-17 | -$192M 10-K, 2024-03-13 | -$178M 10-K, 2024-03-13 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Sandy Macrae | PRESIDENT, CEO AND DIRECTOR | 4, 2026-05-27 |
| Nathalie Dubois-Stringfellow Chief Development Officer at Sangamo Therapeutics, Inc. | SVP-CHIEF DEVELOPMENT OFFICER | 4, 2026-05-27 |
| Scott B. Willoughby | SVP, CHIEF LEGAL OFFICER, SECY | 4, 2026-05-27 |
| Nikunj Jain | Principal Accounting Officer | 4, 2026-05-27 |
| Gregory D. Davis | Head of Research & Technology | 4, 2026-05-27 |
| Prathyusha Duraibabu | PRINCIPAL FINANCIAL OFFICER | 4, 2026-01-26 |
What Sangamo Therapeutics, Inc does
We are a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. We believe our zinc finger epigenetic regulators are ideally suited to potentially address devastating neurology disorders and our capsid engineering platform has demonstrated the ability to expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system, or CNS, in preclinical studies.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 414.3 million (as of May 11, 2026) | 10-Q, May 14, 2026 |
|---|---|---|
| Public float | $153M (as of June 30, 2025) | 10-K/A, April 30, 2026 |
| Reportable segments | 1 (period ending March 31, 2026) | 10-Q, May 14, 2026 |
| Latest proxy statement | Meeting June 12, 2025 (filed April 30, 2025) | DEF 14A, April 30, 2025 |
| Auditor | Ernst & Young LLP (San Mateo, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| April 22, 2026 | Gregory D. Davis Head of Research & Technology | Sale | 69,827 | $17K | Form 4, April 23, 2026 |
| April 21, 2026 | Nathalie Dubois-Stringfellow SVP-CHIEF DEVELOPMENT OFFICER | Sale | 345,942 | $90K | Form 4, April 23, 2026 |
Recent 8-K events
- 8-K filed 2026-10-27
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-10-16
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-09-21
- Item 1.03 Bankruptcy or receivership
- Item 2.01 Completion of acquisition or disposition of assets
- 8-K filed 2026-09-08
- Item 1.03 Bankruptcy or receivership
- Item 2.01 Completion of acquisition or disposition of assets
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-28
- Item 1.01 Entry into a material definitive agreement
- Item 1.03 Bankruptcy or receivership
- 8-K filed 2026-08-13
- Item 8.01 Other events
- 8-K filed 2026-08-12
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-07-20
- Item 1.03 Bankruptcy or receivership
- Item 3.01 Notice of delisting or failure to meet listing standards
- 8-K filed 2026-07-01
- Item 4.01 Changes in registrant's certifying accountant
- Item 8.01 Other events
- 8-K filed 2026-06-23
- Item 1.01 Entry into a material definitive agreement
- Item 1.03 Bankruptcy or receivership
- Item 2.03 Creation of a direct financial obligation
- Item 2.05 Costs associated with exit or disposal activities (restructuring)
Frequently asked questions about Sangamo Therapeutics, Inc
- What does Sangamo Therapeutics, Inc do?
- In its own words, from Item 1 of its 10-K: "We are a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. We believe our zinc finger epigenetic regulators are ideally suited to potentially address devastating neurology disorders and our capsid engineering platform has demonstrated the ability to expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system, or CNS, in preclinical studies."
- What is Sangamo Therapeutics, Inc's revenue?
- $39.6M for the fiscal year ending December 31, 2025, from its 10-K filed March 30, 2026.
- Is Sangamo Therapeutics, Inc profitable?
- Sangamo Therapeutics, Inc reported net income of -$123M for the fiscal year ending December 31, 2025.
- How many employees does Sangamo Therapeutics, Inc have?
- About 142 as of March 27, 2026, as stated in its annual report.
- Who is the CEO of Sangamo Therapeutics, Inc?
- Sandy Macrae, PRESIDENT, CEO AND DIRECTOR, as named in a 4 filed May 27, 2026.
- Where is Sangamo Therapeutics, Inc headquartered?
- Richmond, CA.
- What is Sangamo Therapeutics, Inc's stock ticker?
- SGMOQ on OTC.
- What industry is Sangamo Therapeutics, Inc in?
- Biological Products, (No Diagnostic Substances), SIC code 2836.
- What is Sangamo Therapeutics, Inc's website?
- sangamo.com.
- When does Sangamo Therapeutics, Inc report earnings next?
- December 20, 2026. Source: estimate_8k_pattern.
- Is Sangamo Therapeutics, Inc a public company?
- Yes. Sangamo Therapeutics, Inc files with the SEC under CIK 0001001233 and trades as SGMOQ.
- Who audits Sangamo Therapeutics, Inc?
- Ernst & Young LLP, San Mateo, California, as named in its latest annual report (10-K).
- How many shares of Sangamo Therapeutics, Inc are outstanding?
- 414.3 million shares as of May 11, 2026, from its 10-Q filed May 14, 2026.
- What is Sangamo Therapeutics, Inc's public float?
- $153M as of June 30, 2025, as reported on the cover of its 10-K/A filed April 30, 2026.
- How many business segments does Sangamo Therapeutics, Inc report?
- 1 reportable segment for the period ending March 31, 2026, from its 10-Q filed May 14, 2026.
- When is Sangamo Therapeutics, Inc's annual shareholder meeting?
- June 12, 2025, per its proxy statement (DEF 14A) filed April 30, 2025.
- Have Sangamo Therapeutics, Inc insiders traded stock recently?
- Since April 21, 2026, officers and directors reported 2 open-market sales worth about $107K and 0 purchases on Forms 4 and 5. The most recent: Gregory D. Davis (Head of Research & Technology) sold 69,827 shares on April 22, 2026.